According to some guidelines for the management of gastric cancer, adjuvant chemotherapy is recommended for patients with pT3–4 or node‐positive disease. The aim of this study was to define low‐… Click to show full abstract
According to some guidelines for the management of gastric cancer, adjuvant chemotherapy is recommended for patients with pT3–4 or node‐positive disease. The aim of this study was to define low‐ and high‐risk groups in terms of survival, and to predict the benefit of adjuvant fluoropyrimidine plus oxaliplatin (F‐OX) chemotherapy.
               
Click one of the above tabs to view related content.